Literature DB >> 8142008

p53 mutations in primary human lung tumors and their metastases.

M B Reichel1, H Ohgaki, I Petersen, P Kleihues.   

Abstract

In a total of 26 primary human lung tumors and 60 metastases derived from them, exons 5-8 of the p53 tumor suppressor gene were analyzed by single-strand conformation polymorphism and subsequent direct DNA sequencing of amplified DNA. Mutational inactivation of the p53 gene was identified in four of five squamous cell carcinomas, three of nine adenocarcinomas, and two of nine small-cell carcinomas, the overall incidence being 35%. Point mutations occurred at a similar incidence in exons 5-8, with a preference for G-->T transversions. In seven of nine cases (78%), mutations were identical in the primary tumor and all of its metastases, indicating that in lung tumors, p53 mutations usually precede metastasis and that hematogenic and lymphogenic dissemination of tumor cells to other tissues is not associated with a selection against p53 inactivation. In one case, a kidney metastasis had the same mutation as the primary squamous cell carcinoma, whereas a liver metastasis had no mutation, indicating heterogeneity of the primary lung neoplasm and selective metastasis of mutated and nonmutated tumor cells to kidney and liver, respectively. Only in one liver metastasis was a mutation identified that was neither present in the primary lung tumor nor in a kidney metastasis, suggesting that occasionally p53 mutations occur after metastatic spread.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142008     DOI: 10.1002/mc.2940090208

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  15 in total

1.  Use of non-radioactive detection in SSCP, direct DNA sequencing and LOH analysis.

Authors:  I Petersen; M B Reichel; M Dietel
Journal:  Clin Mol Pathol       Date:  1996-04

Review 2.  [Morphological and molecular pathology of lung cancer].

Authors:  I Petersen
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

3.  Biological resonance for cancer metastasis, a new hypothesis based on comparisons between primary cancers and metastases.

Authors:  Dongwei Gao; Sha Li
Journal:  Cancer Microenviron       Date:  2013-11-10

4.  Patterns of p53 mutations in squamous cell carcinoma of the lung. Acquisition at a relatively early age.

Authors:  J Zheng; Q Shu; Z H Li; J I Tsao; L M Weiss; D Shibata
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

5.  Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas.

Authors:  May P Chan; Komal R Plouffe; Chia-Jen Liu; Nallasivam Palanisamy; Shannon Carskadon; Lili Zhao; Rosalynn M Nazarian; Alison B Durham; Timothy M Johnson; Aleodor A Andea; Rajiv M Patel; Lori Lowe; Douglas R Fullen; Noah A Brown; Scott A Tomlins; Aaron M Udager; Paul W Harms
Journal:  Mod Pathol       Date:  2019-12-19       Impact factor: 7.842

Review 6.  TP53 mutations in nonsmall cell lung cancer.

Authors:  Akira Mogi; Hiroyuki Kuwano
Journal:  J Biomed Biotechnol       Date:  2011-01-18

7.  Discrimination of double primary lung cancer from intrapulmonary metastasis by p53 gene mutation.

Authors:  D Matsuzoe; T Hideshima; K Ohshima; K Kawahara; T Shirakusa; A Kimura
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

8.  Genetic and biochemical alterations in non-small cell lung cancer.

Authors:  Jackie L Johnson; Smitha Pillai; Srikumar P Chellappan
Journal:  Biochem Res Int       Date:  2012-08-15

Review 9.  Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review.

Authors:  James Sherwood; Simon Dearden; Marianne Ratcliffe; Jill Walker
Journal:  J Exp Clin Cancer Res       Date:  2015-09-04

10.  "Unique trend" and "contradictory trend" in discrimination of primary synchronous lung cancer and metastatic lung cancer.

Authors:  Cheng Shen; Huan Xu; Lunxu Liu; Yubin Zhou; Dali Chen; Heng Du; Zhaojie Han; Guowei Che
Journal:  BMC Cancer       Date:  2013-10-09       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.